Earnings call transcript: PT Indosat Tbk Q3 2026 shares fall on heavy spending

Indosat shares fell 6.82% to $1,570 after Q3 revenue declined 2.2% and EBITDA fell 12.4% sequentially to IDR 7 trillion, amid margin pressure and elevated investment. Nine-month revenue rose 11.1% to IDR 25.8 trillion, EBITDA increased 8.8% to IDR 11.1 trillion, and ARPU climbed 17.9% to IDR 46,000. Management reiterated full-year guidance for close to double-digit revenue and EBITDA growth and about IDR 23 trillion of CapEx, excluding GPU spending, while investing in 5G and AI; it said recent cellular trends were improving.

Analysis

The key issue is cash conversion, not the headline growth rate. Biometric cleanup could improve subscriber quality and pricing power over 1–3 months, but lower gross additions also make ARPU gains less valuable if the paying base stops expanding. Track cellular revenue and net additions together; management’s improving September–October commentary is not yet proof of a durable rebound.

The AI plan has an unfavorable timing asymmetry: Indosat bears infrastructure, funding and operating costs before owned compute and enterprise applications can produce meaningful contribution. Long-term GPU contracts may limit near-term upside from higher rental prices, while token economics depend on direct enterprise sales and model-provider costs—not headline capacity or management’s margin target. Treat those targets as unverified until contracts, utilization and segment cash flow are disclosed. Any read-through to NVIDIA (NVDA) is likely immaterial absent evidence of material orders.

Balance-sheet optics also merit scrutiny: FiberCo proceeds supported reported deleveraging, while the CFO cited a sharp sequential rise in net debt. Verify recurring lease, spectrum and maintenance obligations. The reported nine-month CapEx figure and reiterated full-year target appear difficult to reconcile; confirm definitions and timing before underwriting free cash flow. The share-price fall may invite a bounce, but oversold conditions alone do not establish value. Near term, further margin or cash-flow disappointment could outweigh a biometric recovery; over 6–18 months, returns hinge on utilization and monetization rather than announced capacity.

Key Decisions for Investors

• No immediate directional trade: wait for the next operating update to confirm cellular revenue and net additions are recovering together, and for reported EBITDA/cash conversion to stabilize.
• Watch item: reconcile nine-month CapEx with full-year guidance, and separate recurring spectrum, FiberCo/lease and maintenance costs from genuinely one-off items before revising valuation or cash-flow assumptions.
• Keep AI exposure as an execution watch, not an earnings premium: seek disclosed utilization, contracted enterprise revenue, funding completion and realized margins before crediting the capacity and Intelligence Suite targets.
• Falsification: reduce the recovery thesis if cellular revenue remains weak after biometric comparisons normalize, margins deteriorate further, or net debt rises without corresponding disclosed AI utilization and cash generation.